Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)
This non-randomized, open-label study was approximately one year in duration and consisted of a short term NaPBA to HPN-100 switchover part involving two overnight stays followed by a 12-month long term treatment period involving monthly visits.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Switch-Over, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of HPN-100, Followed by Long-Term Treatment With HPN-100, in Pediatric Subjects Under 6 Years of Age With Urea Cycle Disorders (UCDs)|
- Rate of adverse events. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
- Comparison of ammonia control, assessed as 24 hr area under the curve, on NaPBA and HPN-100 (switchover only) [ Time Frame: 10 days ] [ Designated as safety issue: No ]
- Comparative pharmacokinetics of NaPBA and HPN-100 (switchover only) [ Time Frame: 24 hour ] [ Designated as safety issue: No ]Multiple plasma and urine samples will be collected to measure PAA (phenylacetate), PBA (phenylbutyrate / phenylbutyric acid), and PAGN (phenylacetylglutamine).
- Frequency of hyperammonemic crises as compared with prior to enrollment (extension phase) [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
|Study Start Date:||July 2011|
|Study Completion Date:||March 2013|
|Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
This was an open-label study consisting of a 10-day switch-over period during which subjects were switched from their prescribed dose of sodium phenylbutyrate (BUPHENYLTM or NaPBA) to a dose of HPN-100 that delivered the same amount of the active ingredient, PBA, followed by long-term treatment with HPN-100 for up to 12 months. The study was designed to capture information important for evaluating safety, Pharmacokinetics, and efficacy while recognizing sampling limitations in young children and current standard of care. Patients eligible for this study included pediatric patients from 29 days to < 6 years of age with either a diagnosed or clinically suspected Urea Cycle Disorders (UCD) who are receiving a stable dose of the powder formulation of NaPBA. Subjects were clinically stable and had been receiving a stable dose NaPBA powder for at least 5 days at the time of enrollment.
During the switch-over part of the study, subjects switched from NaPBA to HPN-100 in one step and had two overnight stays with 24 hour blood sampling, the first of which was on Day 1, while still taking NaPBA, and the second of which was on approximately Day 10 while taking HPN-100. Subjects then continued in the long-term treatment phase which was 12 months in duration.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01347073
|United States, District of Columbia|
|Children's National Medical Center|
|Washington, District of Columbia, United States|
|United States, Maine|
|Maine Medical Center|
|Portland, Maine, United States|
|United States, Minnesota|
|University of Minnesota|
|Minneapolis, Minnesota, United States|
|United States, New York|
|Mount Sinai School of Medicine|
|New York, New York, United States|
|United States, Ohio|
|University Hospitals Case Medical Center|
|Cleveland, Ohio, United States|
|United States, Oregon|
|Oregon Health & Science University|
|Portland, Oregon, United States|
|United States, Texas|
|Baylor College of Medicine|
|Houston, Texas, United States|